Loss of G1/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1

Journal of Virology

Volumn 74, Issue 11, 2000, Pages 5040-5052

  Clark, Elizabeth ^a   Santiago, Francisco ^a   Deng, Longwen ^a   Chong, Siew Yen ^a   De La Fuente, Cynthia ^a   Wang, Lai ^a   Fu, Peng ^a   Stein, Dana ^b   Denny, Thomas ^b   Lanka, Venkata ^a   Mozafari, Fariba ^c   Okamoto, Takashi ^d   Kashanchi, Fatah ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN P21; PROTEIN P27; PROTEIN P53; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; GAMMA IRRADIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS CELL INTERACTION; VIRUS TITRATION; VIRUS TRANSCRIPTION;

CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL LINE; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; GAMMA RAYS; GENE PRODUCTS, TAT; HIV-1; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; S PHASE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

EID: 0034065253     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.11.5040-5052.2000     Document Type: Article

References (49)

1. Biggs, J. R., and A. S. Kraft. 1995. Inhibitors of cyclin-dependent kinase and cancer. J. Mol. Med. 73:509-514.
2. Bohan, C. A., F. Kashanchi, B. Ensoli, L. Buonaguro, K. A. Boris-Lawrie, and J. N. Brady. 1992. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr. 2:391-407.
3. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
4. Bunz, F., A. Dulriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
5. Chang, I. J., E. McNulty, and M. Martin. 1993. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. J. Virol. 67:743-752.
6. Chen, J., P. Saha, S. Kornbluth, B. D. Dynlacht, and A. Dutta. 1996. Cyclinbinding motifs are essential for the function of p21CIP1. Mol. Cell. Biol. 16:4673-4682.
7. Coffman, F. D., and G. P. Studzinski. 1999. Differentiation-related mechanisms which suppress DNA replication. Exp. Cell Res. 248:58-67.
8. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
9. Duan, L., I. Ozaki, J. W. Oakes, J. P. Taylor, K. Khalili, and R. J. Pomerantz. 1994. The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J. Virol. 68:4302-4313.
10. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. 1989. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86:5974-5978.
11. Drexler, H. G. 1998. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845-859.
12. el-Solh, A., N. M. Kumar, M. P. Nair, S. A. Schwartz, and J. S. Lwebuga-Mukasa. 1997. An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549, Immunol. Investig. 26:351-370.
13. Gartel, A. L., M. S. Serfas, and A. L. Tyner. 1996. p21 - negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med. 213:138-149.
14. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L. H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, et al. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
15. Hofman, F. M., A. D. Wright, M. M. Dohadwala, F. Wong-Staal, and S. M. Walker. 1993. Exogenous tat protein activates human endothelial cells. Blood 82:2774-2780.
16. Iliakis, G. 1997. Cell cycle regulation in irradiated and nonirradiated cells. Semin. Oncol. 24:602-615.
17. Kashanchi, F., J. F. Duvall, and J. N. Brady. 1992. Electroporation of viral transactivator proteins into lymphocyte suspension cells. Nucleic Acids Res. 20:4673-4674.
18. Kashanchi, F., J. F. Duvall, R. P. Kwok, J. R. Lundblad, R. H. Goodman, and J. N. Brady. 1998. The coactivator CBP stimulates human T-cell lymphotrophic virus type I Tax transactivation in vitro. J. Biol. Chem. 273:34646-34652.
19. Kashanchi, F., S. N. Khleif, J. F. Duvall, M. R. Sadaie, M. F. Radonovich, M. Cho, M. A. Martin, S. Y. Chen, R. Weinmann, and J. N. Brady. 1996. Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex. J. Virol. 70:5503-5510.
20. Kashanchi, F., G. Piras, M. F. Radonovich, J. F. Duvall, A. Fattaey, C. M. Chiang, R. G. Roeder, and J. N. Brady. 1994. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 367:295-299.
21. Kastan, M. B., and S. Kuerbitz. 1993. Control of G1 arrest after DNA damage. Environ. Health Perspect. 101:55-58.
22. Kira, T., J. P. Merin, M. Baba, S. Shigeta, and T. Okamoto. 1995. Anti-Tat MTT assay: a novel anti-HIV drug screening system using the viral regulatory network of replication. AIDS Res. Hum. Retroviruses 11:1359-1366.
23. Kootstra, N. A., and H. Schuitemaker. 1998. Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. AIDS Res. Hum. Retroviruses 14:339-345.
24. o lymphocytes. J. Virol. 73: 6526-6532.
25. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72:3161-3168.
26. Li, C. J., C. Wang, D. J. Friedman, and A. B. Pardee. 1995. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92:5461-5464.
27. Longo, F., M. A. Marchetti, L. Castagnoli, P. A. Battaglia, and F. Gigliani. 1995. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins. Biochem. Biophys. Res. Commun. 206:326-334.
28. Lu, H., and A. J. Levine. 1995. Human TAFI131 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92:5154-5158.
29. Mantel, C., S. E. Braun, S. Reid, O. Henegariu, L. Liu, G. Hangoc, and H. E. Broxmeyer. 1999. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 93:1390-1398.
30. Masutani, M., T. Nozaki, K. Wakabayashi, and T. Sugimura. 1995. Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Biochimic 77:462-465.
31. Mundt, M., T. Hupp, M. Fritsche, C. Merkle, S. Hansen, D. Lane, and B. Groner. 1997. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15:237-244.
32. Muralidhar, S., J. Doniger, E. Mendelson, J. C. Araujo, F. Kashanchi, N. Azumi, J. N. Brady, and L. J. Rosenthal. 1996. Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J. Virol. 70:8691-8700.
33. Ogryzko, V. V., P. Wong, and B. H. Howard. 1997. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol. Cell. Biol. 17:4877-4882.
34. Perry, M. E., and A. J. Levine. 1993. Tumor-suppressor p53 and the cell cycle. Curr. Opin. Genet. Dev. 3:50-54.
35. Pise-Masison, C. A., K. S. Choi, M. Radonovich, J. Dittmer, S. I. Kim, and J. N. Brady. 1998. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol. 72:1165-1170.
36. Quillent, C., N. Dumey, C. Dauguet, and F. Clavel. 1993. Reversion of a polymerase-defective integrated HIV-1 genome. AIDS Res. Hum. Retroviruses 9:1031-1037.
37. Rounseville, M. P., and A. Kumar. 1992. Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 transactivation-responsive RNA. J. Virol. 66:1688-1694.
38. Rounseville, M. P., H. C. Lin, E. Agbottah, R. R. Shukla, A. B. Rabson, and A. Kumar. 1996. Inhibition of HIV-1 replication in viral mutants with altered TAR RNA stem structures. Virology 216:411-417.
39. Schuitemaker, H., N. A. Kootstra, R. A. Fouchier, B. Hooibrink, and F. Miedema. 1994. Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J. 13:5929-5936.
40. Seve, M., A. Favier, M. Osman, D. Hernandez, G. Vaitaitis, N. C. Flores, J. M. McCord, and S. C. Flores. 1999. The human immunodeficiency virus-1 Tat protein increases cell proliferation, alters sensitivity to zinc chelator-induced apoptosis, and changes Sp1 DNA binding in HeLa cells. Arch. Biochem. Biophys. 361:165-172.
41. Steegenga, W. T., A. Shvarts, N. Riteco, J. L. Bos, and A. G. Jochemsen. 1999. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins. Mol. Cell. Biol. 19:3885-3894.
42. Stein, G. H., L. F. Drullinger, A. Soulard, and V. Dulic. 1999. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19: 2109-2117.
43. Stein, G. H., and V. Dulic. 1995. Origins of G1 arrest in senescent human fibroblasts. Bioessays 17:537-543.
44. Szumiel, I. 1998. Monitoring and signaling of radiation-induced damage in mammalian cells. Radiat. Res. 150:S92-S101.
45. Tobiume, M., K. Fujinaga, M. Kameoka, T. Kimura, T. Nakaya, T. Yamada, and K. Ikuta. 1998. Dependence on host cell cycle for activation of human immunodeficiency virus type I gene expression from latency. J. Gen. Virol. 79:1363-1371.
46. Wang, P., J. D. Barks, and F. S. Silverstein. 1999. Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats. Neuroscience 88:585-597.
47. Westphal, C. H. 1997. Cell-cycle signaling: Atm displays its many talents. Curr. Biol. 7:R789-R792.
48. Xu, X., T. Nakano, S. Wick, M. Dubay, and L. Brizuela. 1999. Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation. Biochemistry 38:8713-8722.
49. Zimmermann, H., R. Degenkolbe, H. U. Bernard, and M. J. O'Connor. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73: 6209-6219.